Lupus & antiphospholipid syndrome
Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial
Authors' conclusion
KOC corrected omega-3 deficiency in patients with SLE. Supplementation with KOC was safe and decreased disease activity in those with more active disease.
Study context
- Population
- Adults with active SLE
- Participants
- 78 adults
- Comparison
- Krill oil concentrate (KOC) 4 g/day vs placebo for 24 weeks
- KOCn = 39
- Placebon = 39reference
- Primary endpoint
- Improvement of the red blood cell Omega-3 Index from baseline
- Follow-up
- Week 24
Methodological detailsmulticentre, double-blind, placebo-controlled, open-label extension
- Multicentre
- Double-blind
- Placebo-controlled
- Open-label extension
Primary result
As reported in the abstract
Omega-3 Index, mean
KOC
8.05%
mean · SD 1.79%
Further findings
- Omega-3 Index after switch from placebo to KOC at week 24 (open-label extension) · week 48 — Placebo
- mean 7.50% (SD 1.75%)
- Omega-3 Index, KOC · week 4
- 7.17% · mean · SD 1.48%
- Omega-3 Index after switch from placebo to KOC at week 24 (open-label extension) — Increase from 4.63%±1.39% at week 24 (n=26) to 7.50%±1.75% at week 48 (n=12)
- p<0.001
- SLEDAI-2K in high baseline disease activity (SLEDAI-2K ≥9) (subgroup, n=9 per group) · 4, 8 and 16 weeks · week 4; SLEDAI-2K decreased significantly with KOC
- P = 0.04
- SLEDAI-2K in high baseline disease activity (SLEDAI-2K ≥9) (subgroup, n=9 per group) · 4, 8 and 16 weeks · week 8
- P = 0.02
- SLEDAI-2K in high baseline disease activity (SLEDAI-2K ≥9) (subgroup, n=9 per group) · 4, 8 and 16 weeks · week 16
- P = 0.01
Omega-3 Index, KOC · week 4
- p<0.001 vs baseline (n=38)
SLEDAI-2K, overall population · 24 weeks
- No changes in disease activity in the study population overall
Original publication
Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial. Lupus Sci Med. Published 14 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →